Nelarabine

奈拉滨

Report date: 2025/03/26 20:01:25
NMEFirst In Class

Base Information

Drug NameNelarabine
Drug Alias NameNelarabinum奈拉宾nelarabinaArranonAtriance +[12] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA polymerase alpha subunit inhibitors
TargetsDNA polymerase alpha subunit
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaMyeloproliferative DisordersMyelodysplastic Syndromes +[20] 
Global Approved IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/10/28
Country/TerritoryUnited StatesGermanyEU +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGlaxosmithkline PlcNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesSandozGlaxosmithkline PlcSandoz Pharmaceuticals Dd +[4] 
Inactive CompaniesGoethe UniversityNational Cancer Institute
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsAngioimmunoblastic T-cell LymphomaMyeloproliferative DisordersMyelodysplastic Syndromes +[19] 

Other Information

ATC CodeL01BB07
Related LinksWikipediaDrugBankKEGG